KalVista Pharmaceuticals, Inc.
KALV
$14.66
$1.148.43%
NASDAQ
| 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.69M | 1.43M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.69M | 1.43M | -- | -- | -- |
| Cost of Revenue | 13.23M | 15.75M | 15.89M | 12.59M | 18.68M |
| Gross Profit | 467.00K | -14.33M | -15.89M | -12.59M | -18.68M |
| SG&A Expenses | 46.52M | 44.68M | 39.14M | 30.35M | 24.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.74M | 60.44M | 55.03M | 42.94M | 43.48M |
| Operating Income | -46.05M | -59.01M | -55.03M | -42.94M | -43.48M |
| Income Before Tax | -47.33M | -57.94M | -53.08M | -44.26M | -39.08M |
| Income Tax Expenses | 2.16M | 2.16M | -855.00K | 4.25M | -- |
| Earnings from Continuing Operations | -49.48M | -60.10M | -52.23M | -48.51M | -39.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.48M | -60.10M | -52.23M | -48.51M | -39.08M |
| EBIT | -46.05M | -59.01M | -55.03M | -42.94M | -43.48M |
| EBITDA | -45.76M | -58.76M | -54.77M | -42.71M | -43.26M |
| EPS Basic | -0.92 | -1.12 | -0.98 | -0.92 | -0.84 |
| Normalized Basic EPS | -0.56 | -0.68 | -0.63 | -0.53 | -0.53 |
| EPS Diluted | -0.92 | -1.12 | -0.98 | -0.92 | -0.84 |
| Normalized Diluted EPS | -0.56 | -0.68 | -0.63 | -0.53 | -0.53 |
| Average Basic Shares Outstanding | 53.88M | 53.50M | 53.04M | 52.64M | 46.59M |
| Average Diluted Shares Outstanding | 53.88M | 53.50M | 53.04M | 52.64M | 46.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |